• 
• Print
• Email
• Order a PDF

RXi Pharmaceuticals Corp. of Worcester has received the green light from the U.S. Food and Drug Administration (FDA) to start clinical trials for a drug that would reduce scarring from surgery.

"RXi's next-generation RNAi platform has shown great promise," said President and CEO Dr. Geert Cauwenbergh. "As we aggressively pursue the potential of this compound for this condition with major social impact, we will also continue to work to create long-term shareholder value."

Read more

RXi Awarded Funding For Cancer Therapy

With Clinical Trial Ongoing, RXi Losses Climb

• 
• Print
• Email
• Order a PDF